DK3319963T3 - Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer - Google Patents

Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer Download PDF

Info

Publication number
DK3319963T3
DK3319963T3 DK16741469.7T DK16741469T DK3319963T3 DK 3319963 T3 DK3319963 T3 DK 3319963T3 DK 16741469 T DK16741469 T DK 16741469T DK 3319963 T3 DK3319963 T3 DK 3319963T3
Authority
DK
Denmark
Prior art keywords
substituted
receptor modulators
glun2b receptor
aza indoles
indoles
Prior art date
Application number
DK16741469.7T
Other languages
English (en)
Inventor
Christa C Chrovian
Michael A Letavic
Jason C Rech
Akinola Soyode-Johnson
Jessica L Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3319963T3 publication Critical patent/DK3319963T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK16741469.7T 2015-07-09 2016-07-07 Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer DK3319963T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
DK3319963T3 true DK3319963T3 (da) 2020-02-03

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16741469.7T DK3319963T3 (da) 2015-07-09 2016-07-07 Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer

Country Status (25)

Country Link
US (2) US9963447B2 (da)
EP (1) EP3319963B1 (da)
JP (2) JP6964576B2 (da)
KR (1) KR20180026760A (da)
CN (1) CN108026094B (da)
AU (1) AU2016291158B2 (da)
BR (1) BR112018000468A2 (da)
CA (1) CA2991765C (da)
CY (1) CY1123007T1 (da)
DK (1) DK3319963T3 (da)
EA (1) EA033197B1 (da)
ES (1) ES2781867T3 (da)
HK (1) HK1255160A1 (da)
HR (1) HRP20200410T1 (da)
HU (1) HUE047460T2 (da)
IL (1) IL256758A (da)
LT (1) LT3319963T (da)
MA (1) MA42397B1 (da)
MD (1) MD3319963T2 (da)
MX (1) MX2018000352A (da)
PL (1) PL3319963T3 (da)
PT (1) PT3319963T (da)
SI (1) SI3319963T1 (da)
WO (1) WO2017007938A1 (da)
ZA (1) ZA201800827B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
EP3180315B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Pyrazoles
ES2781867T3 (es) * 2015-07-09 2020-09-08 Janssen Pharmaceutica Nv 4-Azaindoles sustituidos y su utilización como moduladores del receptor GluN2B
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
EP3982958A1 (en) * 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
MX2021015508A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de piridina y su uso como moduladores del receptor glun2b.
US20220324860A1 (en) * 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CR20210580A (es) * 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
JP2022536773A (ja) * 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用
CN114621125A (zh) * 2020-12-14 2022-06-14 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100368411C (zh) * 2002-03-28 2008-02-13 卫材R&D管理有限公司 作为c-Jun N-末端激酶抑制剂用于治疗神经变性疾病的7-氮杂吲哚类化合物
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
WO2007115231A2 (en) * 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009005821A1 (en) 2007-07-03 2009-01-08 Edward Scott Carlson Support apparatus for climbing plants
CA2697663A1 (en) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
WO2009118187A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2308877B1 (en) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
JP5656848B2 (ja) * 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ, インコーポレイテッド. 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
CA2901334A1 (en) * 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
PE20151997A1 (es) * 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
EP3180315B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Pyrazoles
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
ES2781867T3 (es) 2015-07-09 2020-09-08 Janssen Pharmaceutica Nv 4-Azaindoles sustituidos y su utilización como moduladores del receptor GluN2B
WO2017139428A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途

Also Published As

Publication number Publication date
CY1123007T1 (el) 2021-10-29
AU2016291158A1 (en) 2018-02-01
EP3319963B1 (en) 2020-01-08
MA42397B1 (fr) 2020-02-28
CA2991765C (en) 2023-10-03
EA033197B1 (ru) 2019-09-30
HUE047460T2 (hu) 2020-04-28
US10377753B2 (en) 2019-08-13
US20180208595A1 (en) 2018-07-26
ZA201800827B (en) 2019-09-25
EA201890245A1 (ru) 2018-06-29
LT3319963T (lt) 2020-03-25
US9963447B2 (en) 2018-05-08
JP7369743B2 (ja) 2023-10-26
US20170008890A1 (en) 2017-01-12
EP3319963A1 (en) 2018-05-16
JP2021193099A (ja) 2021-12-23
MX2018000352A (es) 2018-08-15
AU2016291158B2 (en) 2020-04-30
WO2017007938A1 (en) 2017-01-12
PL3319963T3 (pl) 2020-06-01
CN108026094B (zh) 2021-02-09
JP2018520170A (ja) 2018-07-26
ES2781867T3 (es) 2020-09-08
CA2991765A1 (en) 2017-01-12
CN108026094A (zh) 2018-05-11
KR20180026760A (ko) 2018-03-13
HRP20200410T1 (hr) 2020-08-21
HK1255160A1 (zh) 2019-08-09
PT3319963T (pt) 2020-04-09
IL256758A (en) 2018-03-29
JP6964576B2 (ja) 2021-11-10
BR112018000468A2 (pt) 2018-09-18
SI3319963T1 (sl) 2020-02-28
MD3319963T2 (ro) 2020-05-31

Similar Documents

Publication Publication Date Title
DK3319963T3 (da) Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer
DK3490565T3 (da) Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3233852T3 (da) Tetrahydro-pyrido[3,4-b]indoler som østrogenreceptormodulatorer og anvendelser deraf
DK3359160T3 (da) Farnesoid x receptor modulatorer
MA53943A (fr) Modulateurs de ror-gamma
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3331876T3 (da) Modulators of ror-gamma
MA55328A (fr) Modulateurs de ror-gamma
DK3363438T3 (da) Substituerede 2-azabicykler og deres anvendelse som orexinreceptormodulatorer
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
DK3322701T3 (da) Ethynylderivater som metabotropiske glutamatreceptormodulatorer
DK3074011T3 (da) Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer
DK3331863T3 (da) Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK3129366T3 (da) Carbazol-indeholdende amider, carbamater og urinstoffer som kryptokrommodulatorer
DK3288940T3 (da) Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer
DK3377483T3 (da) N-substituerede indolderivater som pge2-receptormodulatorer
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3625228T3 (da) Pyrimidinderivater som pge2-receptormodulatorer
DK3126361T3 (da) Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
DK3214079T3 (da) Seks-leddede benzodiazepinderivater som dpp-4-inhibitorer og hvordan de bruges
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
DK3371168T3 (da) Indolin-2-on-derivater